Study of C1GALT1C1: Potential Drug Target for Neurological Disorders

Target Name: C1GALT1C1

NCBI ID: G29071

C1GALT1C1

Study of C1GALT1C1: Potential Drug Target for Neurological Disorders

C1GALT1C1 (C38H2-L1), a protein found in the brain, has been identified as a potential drug target (or biomarker) for various neurological and psychiatric disorders. Its unique structure and function have made it an attractive target for researchers to study and develop new treatments.

C1GALT1C1 is a transmembrane protein that is expressed in many different tissues, including the brain. It is made up of 38 amino acids and has a calculated molecular weight of 41 kDa. C1GALT1C1 is primarily localized to the endoplasmic reticulum (ER) and is also found in the cytoplasm.

One of the unique features of C1GALT1C1 is its unique shape. It has a molecular shape that is elongated in the direction of its long axis and has a bent shape at its opposite end. This shape allows C1GALT1C1 to interact with other proteins in the ER and to influence the movement of those proteins.

Another interesting feature of C1GALT1C1 is its role in the regulation of cellular processes. It is involved in the regulation of the levels of various molecules in the cell, including enzymes, neurotransmitters, and signaling proteins. It is also involved in the regulation of cellular signaling pathways, including the production of neurotransmitters and the modulation of gene expression.

In addition to its role in cellular signaling, C1GALT1C1 is also thought to be involved in the development and progression of certain neurological and psychiatric disorders. For example, it has been shown to be involved in the development of Alzheimer's disease, a degenerative brain disorder that is characterized by the progressive loss of memory and the accumulation of beta-amyloid plaques in the brain.

C1GALT1C1 is also thought to be involved in the development of other psychiatric disorders, including depression and anxiety. Studies have shown that C1GALT1C1 levels are often reduced in individuals with depression and anxiety and that inhibiting its activity may be an effective way to treat these disorders.

Due to its unique shape and its involvement in cellular signaling pathways, C1GALT1C1 has potential as a drug target. Researchers are currently working to identify small molecules that can interact with C1GALT1C1 and to study their potential therapeutic effects. These small molecules may include drugs that can inhibit the activity of C1GALT1C1, drugs that can modulate its expression, or drugs that can interfere with its function.

In conclusion, C1GALT1C1 is a protein that has unique structure and function and is involved in the regulation of cellular processes. Its potential as a drug target makes it an attractive target for researchers to study and develop new treatments for a variety of neurological and psychiatric disorders. Further research is needed to fully understand the role of C1GALT1C1 in the development and progression of these disorders and to identify effective small molecules that can interact with it.

Protein Name: C1GALT1 Specific Chaperone 1

Functions: Probable chaperone required for the generation of 1 O-glycan Gal-beta1-3GalNAc-alpha1-Ser/Thr (T antigen), which is a precursor for many extended O-glycans in glycoproteins. Probably acts as a specific molecular chaperone assisting the folding/stability of core 1 beta-3-galactosyltransferase (C1GALT1)

The "C1GALT1C1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C1GALT1C1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets